Cytotoxic effects of antiglypican-3 against HepG2 cell line


Article history: Received on: 05/12/2013 Revised on: 16/12/2013 Accepted on: 23/12/2013 Available online: 30/12/2013 For decades, various systemic therapies have been explored for the treatment of advanced hepatocellular carcinoma (HCC), the fifth most common cancer and the third leading cause of cancer-related deaths worldwide. Nevertheless, no… (More)


3 Figures and Tables

Slides referencing similar topics